B+
Bull case
25%
Probability
Target price
$9.25
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
INNV
InnovAgeFNasdaq / Health Care Equipment & Services
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
50%
Probability
Target price
$7.25
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$5.75
Analysis reference price unavailable
Analysis 2026-05-08 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-05-08
Recent news sentiment (30D)
+0.1
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
+30.0
Positive
Sentiment proxy
+22.7
Score
AI commentary
This is still a monitoring-style post-earnings memo rather than a clean bullish upgrade. Company-source evidence is strong and the initial May 5, 2026 earnings reaction was positive, but by May 8, 2026 the stock was about $8.00 versus the $8.08 May 7 anchor, implying much of the first pop had faded. Analyst revision visibility remains thin, so the better tone from the earnings package should raise attention more than conviction.
RankAlpha Sentiment Codex - 2026-05-08
Open post-earnings memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-06-30catalystCash build and operating cash flow reduce immediate financing pressureMedium impact
InnovAge ended March 31, 2026 with $95.5 million of cash, $43.1 million of short-term investments, $69.4 million of debt, and $43.4 million of operating cash flow for the first nine months of fiscal 2026, which lowers near-term balance-sheet risk even if it is not a standalone rerating driver [#10-Q-2026-05-08] [#8-K-2026-05-05].
2026-09-09eventQ4/FY2026 report must prove the Q3 guide raise can survive a tougher FY2027 rate backdropHigh impact
The May 5 earnings package raised FY2026 revenue guidance to $950-$975 million and Adjusted EBITDA to $85-$90 million, but management also said early FY2027 Medicaid indications look softer and Medicare rate growth may be only about 1.5%-2.0%, making the next quarterly update the key proof point for whether current margin gains are durable [#8-K-2026-05-05].
2026-12-31catalystCenter-level margin gains can continue if census growth and care-cost control holdHigh impact
Q3 revenue rose 15.5% year over year to $251.9 million, center-level contribution margin improved to 24.2% from 18.7%, and management attributed the improvement to higher capitation rates, member-month growth, lower nursing-facility utilization, in-house pharmacy benefits, and better medical-cost discipline while newer Florida centers continue to mature [#8-K-2026-05-05] [#10-K-2025-09-09].
Recommendation
N/A
No formal recommendation provided.
As of 2026-05-08 • Updated nightlySource: Internal modelMethodology